| Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial. | |
| | |
MedLine Citation:
|
PMID: 10383513 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: H2-receptor antagonists are widely used in patients with gastro-oesophageal reflux disease (GERD) and are frequently continued when symptoms persist. Aim: To compare the efficacy of omeprazole 20 mg once daily with that of ranitidine 150 mg twice daily in relieving GERD symptoms, in patients who remained symptomatic following a 6-week course of ranitidine therapy. METHODS: Patients with heartburn on at least 4 days/week but who did not have endoscopy to assess oesophageal mucosa could participate. This two-phase, prospective trial included a 6-week open-label phase (phase I), followed by an 8-week double-blind phase (phase II). Patients still symptomatic following treatment with ranitidine 150 mg twice daily (phase I) were randomized to double-blind treatment (phase II) with either omeprazole 20 mg once daily or ranitidine 150 mg twice daily. The primary efficacy variable was the proportion of patients with heartburn resolution during weeks 4 and 8 of phase II. RESULTS: Of the 533 patients with GERD who received ranitidine in phase I, 348 patients (65%) were still symptomatic. A total of 317 patients (59%) were randomized to double-blind treatment (phase II). At week 8, a significantly (P < 0.0004) greater proportion of omeprazole-treated patients (70%) experienced no more than mild heartburn compared with ranitidine-treated patients (49%). Complete resolution of heartburn also occurred in a significantly (P < 0. 00001) greater proportion of omeprazole-treated patients (46% vs. 16% of the ranitidine group at week 8). CONCLUSIONS: After 6 weeks of ranitidine treatment, the majority of patients with GERD were still experiencing moderate to severe heartburn. Omeprazole was significantly more effective than ranitidine in resolving heartburn in this group of patients. |
| | |
Authors:
|
P N Maton; R Orlando; B Joelsson |
Related Documents
:
|
1882903 - Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, place... 6328683 - Long-term treatment of duodenal ulcer. 10214463 - Burch bladder neck colposuspension, comparison of early and late results. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 13 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 1999 Jun |
Date Detail:
|
Created Date: 1999-07-20 Completed Date: 1999-07-20 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 819-26 Citation Subset: IM |
Affiliation:
|
Digestive Disease Research Institute, Oklahoma City, Oklahoma 73104, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anti-Ulcer Agents / therapeutic use* Double-Blind Method Female Gastroesophageal Reflux / drug therapy* Histamine H2 Antagonists / therapeutic use Humans Male Middle Aged Omeprazole / adverse effects, therapeutic use* Prospective Studies Ranitidine / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Ulcer Agents; 0/Histamine H2 Antagonists; 66357-35-5/Ranitidine; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of...
Next Document: Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer...